Jounce Therapeutics, Inc.

Symbol: JNCE

NASDAQ

1.88

USD

Market price today

  • 4.8670

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 98.95M

    MRK Cap

  • 0.00%

    DIV Yield

Jounce Therapeutics, Inc. (JNCE) Financial Statements

On the chart you can see the default numbers in dynamics for Jounce Therapeutics, Inc. (JNCE). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Jounce Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014

balance-sheet.row.cash-and-short-term-investments

622.13189.5220.2213.2
170.4
189.9
235.7
149.3
45.2
2.3

balance-sheet.row.short-term-investments

256.3398359
115.6
142
212.1
104.4
0
0

balance-sheet.row.net-receivables

0000
0
0.4
17.7
0.7
0
0

balance-sheet.row.inventory

0000
0
0
0
0
0
0

balance-sheet.row.other-current-assets

37.217.712.34.9
4.9
1.9
2.2
1.8
0.6
0.5

balance-sheet.row.total-current-assets

659.34197.2190.8211.4
173.7
192.2
255.6
151.8
45.7
2.9

balance-sheet.row.property-plant-equipment-net

55.8912.316.822.2
28.3
13.5
16.2
7.2
5.1
4.3

balance-sheet.row.goodwill

0000
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0

balance-sheet.row.long-term-investments

46.39041.76.7
1.6
6
22.2
108.1
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

12.5833.53.9
2.3
2.7
2.7
4.2
2.2
0.3

balance-sheet.row.total-non-current-assets

114.8615.361.932.8
32.2
22.2
41.1
119.5
7.3
4.7

balance-sheet.row.other-assets

0000
0
0
0
0
0
0

balance-sheet.row.total-assets

774.2212.6252.7244.2
205.9
214.5
296.7
271.3
53
7.5

balance-sheet.row.account-payables

8.552.11.72
2.5
3.3
2.8
3.5
2.6
0.8

balance-sheet.row.short-term-debt

15.894.23.73.3
2.9
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

29.785.91013.6
16.9
0
0
0
0
0

Deferred Revenue Non Current

0000
0
42.7
65
107.3
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-

balance-sheet.row.other-current-liab

60.8217.30.112.1
0.1
7.1
8.6
6.6
4.1
1.7

balance-sheet.row.total-non-current-liabilities

29.785.91013.6
16.9
44.8
67
108.8
1.4
5.6

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

45.671013.716.9
19.8
0
0
0
0
0

balance-sheet.row.total-liab

115.0429.428.932.9
31.3
110.3
129.6
199.4
8.1
8.1

balance-sheet.row.preferred-stock

0000
0
0
296.7
139
103
27.3

balance-sheet.row.common-stock

0.20.10.10
0
0
0
1.9
0.7
0.2

balance-sheet.row.retained-earnings

-1228.54-292.8-241.9-151
-107.2
-163.9
-89.6
-73.2
-59.5
-28

balance-sheet.row.accumulated-other-comprehensive-income-loss

-3.71-0.7-0.20
0.1
-0.1
-0.4
-0.4
0
0

balance-sheet.row.other-total-stockholders-equity

1891.2476.5465.9362.3
281.7
268.1
-39.6
4.5
0.7
0

balance-sheet.row.total-stockholders-equity

659.16183.1223.8211.3
174.6
104.1
167.1
71.9
44.9
-0.5

balance-sheet.row.total-liabilities-and-stockholders-equity

774.2212.6252.7244.2
205.9
214.5
296.7
271.3
53
7.5

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0

balance-sheet.row.total-equity

659.16183.1223.8211.3
174.6
104.1
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

774.2---
-
-
-
-
-
-

Total Investments

302.6939124.765.7
117.2
148
234.3
212.5
0
0

balance-sheet.row.total-debt

45.671013.716.9
19.8
0.1
0.1
0
0
0

balance-sheet.row.net-debt

-320.17-140.6-81.8-130.6
-33.5
-47.8
-23.5
-44.8
-45.2
-2.3

Cash Flow Statement

The financial landscape of Jounce Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014

cash-flows.row.net-income

-50.92-50.9-90.9-43.8
56.8
-27.4
-16.4
-13.7
-28.5
-10.5

cash-flows.row.depreciation-and-amortization

2.092.12.83.4
3.9
3.8
4.4
1.9
1.5
1.1

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

10.2710.311.59.8
9.6
9.4
4.8
5
1.4
0.3

cash-flows.row.change-in-working-capital

8.888.9-7.82.8
-98.9
-48.4
-84.7
186.1
1.8
-0.3

cash-flows.row.account-receivables

0000
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0

cash-flows.row.account-payables

0.420.4-0.3-0.3
-0.9
0.6
0.4
-0.3
0.7
-0.3

cash-flows.row.other-working-capital

8.468.5-7.53.1
-98
-48.9
-85.1
186.4
1.2
0

cash-flows.row.other-non-cash-items

0.80.80.90
-1.5
-1.1
1.2
0.3
-1.9
-5.5

cash-flows.row.net-cash-provided-by-operating-activities

-28.88000
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.92-0.9-0.4-0.1
-1
-1.4
-15.1
-2.2
-2.2
-0.7

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-24.93-24.9-130.3-85.9
-189
-252.9
-179.9
-213.3
0
0

cash-flows.row.sales-maturities-of-investments

109.33109.370.1137.3
221.4
340.7
157
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0.1
0

cash-flows.row.net-cash-used-for-investing-activites

83.4883.5-60.551.3
31.4
86.4
-38
-215.5
-2.1
-0.7

cash-flows.row.debt-repayment

0000
0
0
0
0
0
0

cash-flows.row.common-stock-issued

0.440.490.870.1
3.6
0
107
0.1
0.1
0

cash-flows.row.common-stock-repurchased

00055.7
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0

cash-flows.row.other-financing-activites

001.2-55.1
0.4
1.5
0.5
35.5
70.6
15

cash-flows.row.net-cash-used-provided-by-financing-activities

0.440.49270.7
4.1
1.5
107.5
35.5
70.7
15

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

55.0455-5294.3
5.3
24.3
-21.3
-0.3
42.8
-0.6

cash-flows.row.cash-at-end-of-period

370.92151.896.8148.8
54.5
49.2
23.6
44.8
45.2
2.3

cash-flows.row.cash-at-beginning-of-period

315.8796.8148.854.5
49.2
24.8
44.8
45.2
2.3
3

cash-flows.row.operating-cash-flow

-28.88-28.9-83.5-27.8
-30.1
-63.6
-90.7
179.7
-25.7
-14.9

cash-flows.row.capital-expenditure

-0.92-0.9-0.4-0.1
-1
-1.4
-15.1
-2.2
-2.2
-0.7

cash-flows.row.free-cash-flow

-29.8-29.8-83.9-27.9
-31.1
-65
-105.8
177.5
-27.9
-15.6

Income Statement Row

Jounce Therapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of JNCE is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014

income-statement-row.row.total-revenue

828226.962.3
147.9
65.2
71.6
37.2
0
0

income-statement-row.row.cost-of-revenue

0000
0
0
0
0
0
0

income-statement-row.row.gross-profit

828226.962.3
147.9
65.2
71.6
37.2
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0

income-statement-row.row.research-development

103.27---
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

30.97---
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.461.50.21.3
4.1
0
0
0
0
0

income-statement-row.row.operating-expenses

134.24134.2118107.5
95.1
96.5
90.9
51.7
30.4
16.2

income-statement-row.row.cost-and-expenses

134.24134.2118107.5
95.1
96.5
90.9
51.7
30.4
16.2

income-statement-row.row.interest-income

0000
0
0
0
0
0
0

income-statement-row.row.interest-expense

-1.46-1.500
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.461.50.21.3
4.1
4
2.8
0.8
1.9
5.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.461.50.21.3
4.1
0
0
0
0
0

income-statement-row.row.total-operating-expenses

1.461.50.21.3
4.1
4
2.8
0.8
1.9
5.7

income-statement-row.row.interest-expense

-1.46-1.500
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

2.092.12.83.4
3.9
3.8
4.4
1.9
1.5
1.1

income-statement-row.row.ebitda-caps

-50.16---
-
-
-
-
-
-

income-statement-row.row.operating-income

-52.24-52.2-91.1-45.1
52.8
-31.3
-19.2
-14.5
-30.4
-16.2

income-statement-row.row.income-before-tax

-50.78-50.8-90.9-43.8
56.9
-27.3
-16.4
-13.7
-28.5
-10.5

income-statement-row.row.income-tax-expense

0.140.100
0
0
0
0.8
1.9
5.7

income-statement-row.row.net-income

-50.92-50.9-90.9-43.8
56.8
-27.4
-16.4
-13.7
-28.5
-10.5

Frequently Asked Question

What is Jounce Therapeutics, Inc. (JNCE) total assets?

Jounce Therapeutics, Inc. (JNCE) total assets is 212550000.000.

What is enterprise annual revenue?

The annual revenue is 82000000.000.

What is firm profit margin?

Firm profit margin is 1.000.

What is company free cash flow?

The free cash flow is 0.527.

What is enterprise net profit margin?

The net profit margin is 0.243.

What is firm total revenue?

The total revenue is 0.231.

What is Jounce Therapeutics, Inc. (JNCE) net profit (net income)?

The net profit (net income) is -50919000.000.

What is firm total debt?

The total debt is 10020000.000.

What is operating expences number?

The operating expences are 134242000.000.

What is company cash figure?

Enretprise cash is 150572000.000.